Patients receiving sulfonylureas or insulin: Acarbose Chronic stable angina (unlabeled use): Usual dose: given in combination with a sulfonylurea or insulin will 400-1200 mg/day in 2 divided doses (Gibbons, 2002); cause a further lowering of blood glucose and may low doses (ie, 400 mg/day) may also be given as once increase the hypoglycemic potential of the sulfonylurea daily (Pina, 1988) or insulin. If hypoglycemia occurs, appropriate adjust- Elderly: Consider dose reduction due to age-related ments in the dosage of these agents should be made. increase in bioavailability; do not exceed 800 mg/day. Dosing adjustment in renal impairment: In the management of hypertension, consider lower initial Clcr <25 mL/minute: Peak plasma concentrations were 5 dose (eg, 200-400 mg/day) and titrate to response (Aro- times higher and AUCs were 6 times larger than in now, 2011). volunteers with normal renal function. Dosing adjustment in renal impairment: Significant renal dysfunction (S >2 mg/dL): Use is not cr Cl 25-49 mL/minute: Reduce dose by 50%. recommended. cr Cl <25 mL/minute: Reduce dose by 75%. Dietary Considerations Take with food (first bite of meal). cr Dosing adjustment in hepatic impairment: There are no Administration Should be administered with the first bite dosage adjustments provided in manufacturer's labeling; of each main meal. use with caution. Monitoring Parameters Postprandial glucose, glycosy- Additional Information Complete prescribing information lated hemoglobin levels, serum transaminase levels for this should be consulted for additional should be checked every 3 months during the first year detail. of treatment and periodically thereafter, renal function Dosage Forms Excipient information presented when (serum creatinine); blood pressure available (limited, particularly for generics); consult specific Reference Range Recommendations for glycemic control product labeling. in adults with diabetes: Capsule, oral, as hydrochloride: 200 mg, 400 mg Hb A1c: <7% Sectral®: 200 mg, 400 mg Preprandial capillary plasma glucose: 70-130 mg/dL Peak postprandial capillary blood glucose: <180 mg/dL ^ Acebutolol Hydrochloride see Acebutolol on page 27 Dosage Forms Excipient information presented when available (limited, particularly for generics); consult specific Aceclofenac [INT] (a se KLO fe nak) product labeling. Tablet, oral: 25 mg, 50 mg, 100 mg International Brand Names Air-Tal (BE); Airtal (ES, PT); Precose®: 25 mg, 50 mg, 100 mg Aital (NL); Barcan (DK, NO, SE); Beofenac (AT, DE, PT); Berlofen (AR); Biofenac (BE, NL); Bristaflam (AR, MX); ^ A-Caro-25 [OTC] see Beta-Carotene on page 220 Falcol (ES); Gerbin (ES); Locomin (CH); Preservex (GB); ^ Accel-Amlodipine (Can) see AmLODIPine on page 103 Proflam (BR, IT); Sanein (ES) ^ Accel-Pioglitazone (Can) see Pioglitazone Pharmacologic Category , Nonsteroidal Anti- on page 1455 inflammatory Drug ^ Accolate® see Zafirlukast on page 1936 Reported Use Treatment of pain and inflammation in , , and ankylosing spondy- ^ AccuNeb® see Albuterol on page 57 litis ^ Accupril® see Quinapril on page 1551 Dosage Range Adults: Oral: 100 mg twice daily ^ Accutane see ISOtretinoin on page 1006 Product Availability Product available in various coun- ^ Accutane® (Can) see ISOtretinoin on page 1006 tries; not currently available in the U.S. ^ ACE see Captopril on page 298 Dosage Forms Tablet: 100 mg

Acebutolol (a se BYOO toe lole) Acemetacin [INT] (ay se MET a sin) Brand Names: U.S. Sectral® Brand Names: Canada Apo-Acebutolol®; Mylan-Acebu- International Brand Names Acemetacin Heumann (DE); tolol; Mylan-Acebutolol (Type S); Novo-Acebutolol; Nu- Acemetacin intermuti (DE); Acemetacin Stada (DE); ace- Acebutolol; Rhotral; Sandoz-Acebutolol; Sectral®; Teva- metacin von ct (DE); Acemix (IT); Acephlogont (DE); Altren Acebutolol (BE); Analgel (AR); Azeat (DE); Emflex (GB); Espledol (ES); Flamarion (AR); Gynalgia (AR); Mostanol (DE); Index Terms Acebutolol Hydrochloride Oldan (ES); Rantudil (DE, LU, MX, PT); Rheutrop (AT); Pharmacologic Category Antiarrhythmic Agent, Class II; Solart (IT); Tilur (CH) Beta Blocker With Intrinsic Sympathomimetic Activity Pharmacologic Category Nonsteroidal Anti-inflamma- Additional Appendix Information tory Drug (NSAID), Oral Beta-Blockers on page 2015 Reported Use Treatment of rheumatoid arthritis, osteo- Use Treatment of hypertension; management of ventricular arthritis, low back pain, and postoperative pain and inflam- arrhythmias mation Unlabeled Use Treatment of chronic stable angina (Note: Dosage Range Adults: Oral: Initial: 120 mg/day in divided Not recommended for patients with prior MI) doses; may increase to 180 mg/day in divided doses, Pregnancy Risk Factor B based on patient response Dosage Oral: Product Availability Product available in various coun- Adults: tries; not currently available in the U.S. Ventricular arrhythmias: Initial: 400 mg/day in 2 divided Dosage Forms doses; maintenance: 600-1200 mg/day in divided Capsule: 60 mg doses; maximum: 1200 mg/day Capsule, extended release: 90 mg Hypertension: 400-800 mg/day (larger doses may be divided); maximum: 1200 mg/day; usual dose range ^ Acenocoumarin see Acenocoumarol [CAN/INT] (JNC 7): 200-800 mg/day in 2 divided doses on page 28

27